IDEAYA Biosciences, Inc. (IDYA) stock
Close on Nov 12, 2026Market cap $3.04BP/E –Yield –
IDEAYA Biosciences, Inc. reported revenue of $234.13M for the twelve months to Jun 30, 2026. Free cash flow was -$113.87M. At the latest close the market valued the company at $3.04B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $3.04B
- P/E ratio
- –
- Price to sales
- 12.98
- Price to book
- 2.53
- Dividend yield
- –
- Free cash flow yield
- -3.75%
Fundamentals
- Revenue
- $234.13M
- Net income
- -$175.02M
- EPS, diluted
- -$1.94
- Free cash flow
- -$113.87M
- Book value per share
- $13.02
- Diluted shares
- 92M
Trading
- Next earnings
- Feb 16, 2027 (estimated, before the open)
- Previous close
- $32.72
- Open
- $32.07
- Day's range
- $31.43 – $32.51
- Volume
- 615,932
- Average volume (20 days)
- 1,062,997
- Index membership
- Russell 2000 (since Jun 2020), Russell 3000 (since Aug 2020)
- Beta (5 years)
- 0.78
- 52-week range
- $26.81 – $42.68
- RSI (14 days)
- 45.5
- Volatility (1 year)
- 44.8%
- Relative volume
- 0.91×
- WACC
- 8.8%
On 1 of our idea list: Institutions accumulating
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | IDYA | S&P 500 | Difference | IDYA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -12.7% | -2.7% | −10.0 pts | ||
| 3 months | -14.8% | -1.7% | −13.1 pts | ||
| Year to date | -8.9% | +11.9% | −20.8 pts | ||
| 1 year | -1.4% | +12.0% | −13.4 pts | ||
| 3 years | +7.1% | +78.2% | −71.0 pts | +2.3% | +21.2% |
| 5 years | +36.7% | +73.2% | −36.5 pts | +6.5% | +11.6% |
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases IDEAYA Biosciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Results
- Results
- Update
About IDEAYA Biosciences
Pharmaceutical Preparations
IDEAYA Biosciences, Inc. is a precision medicine oncology company that discovers and develops targeted therapeutics for cancer patients. The company focuses on developing synthetic lethality therapies and antibody-drug conjugates directed at molecularly defined solid tumors. Its clinical pipeline includes darovasertib, a protein kinase C inhibitor evaluated for the treatment of uveal melanoma, as well as investigational programs targeting the MTAP pathway and DNA damage response mechanisms. IDEAYA evaluates its drug candidates as monotherapies and in rational combinations for patients with specific genetic alterations, while collaborating with pharmaceutical partners to advance clinical development.
Company profile, executives and historyIDEAYA Biosciences stock: common questions
What is IDEAYA Biosciences's stock price?
IDYA closed at $31.49 on Nov 12, 2026, down 3.74% on the day. Over the past 52 weeks it traded between $26.81 and $42.68.
What is IDEAYA Biosciences's market cap?
IDEAYA Biosciences was worth $3.04B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is IDYA's P/E ratio?
IDEAYA Biosciences lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.94), so it has no meaningful P/E ratio.
How much revenue does IDEAYA Biosciences make?
IDEAYA Biosciences reported revenue of $234.13M for the twelve months to Jun 30, 2026.
Does IDEAYA Biosciences pay a dividend?
No. IDEAYA Biosciences has not paid a cash dividend over the last twelve months.
When does IDEAYA Biosciences report earnings next?
IDEAYA Biosciences is expected to report Q4 FY2026 results on Feb 16, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has IDYA stock performed over the past year?
Including dividends, IDYA returned -1.4% over the past year, against +12.0% for the S&P 500.
How many IDYA shares are sold short?
8M shares were sold short at the latest FINRA report, 8.61% of the float, or 8.9 days of average trading volume.
Who are IDEAYA Biosciences's competitors?
Companies most similar to IDEAYA Biosciences by business, industry and size include PBYI, ANAB, SNDX, ZYME, NUVB.
See a number that looks wrong?